RxDoctor Payments Data

Joshua Wilson, MD

Dermatology · West Des Moines, IANPI 1447373832

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.8% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 27.3% of the total. 2025 is the largest year on record at $1,021, 2.4 times the $419 reported in 2019.

$4,343in general payments, 2019–2025

Across 225 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$359
  • Novartis$327
  • UCB, Inc.$326
  • Johnson & Johnson$304
  • Sanofi$259
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$3,98692%
  • Education$3588%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,343 in reported general payments places this provider in the 80th percentile of 92 dermatology providers in Iowa.

See all dermatology providers in Iowa

Medicare billing

Part B allowed, 2024
$1,344,476
Medicare patients
1,738
Services billed
12,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab39$394,302
Cosentyx Sensoready (2 Pens)Secukinumab18$159,121
Dupixent PenDupilumab24$92,823
Clobetasol Propionate93$4,984
Acitretin22$3,754
Fluorouracil36$3,005
Fluocinonide75$2,960
Doxycycline Hyclate84$1,712
Dapsone24$1,711
Betamethasone Dipropionate32$1,610
Hydroxychloroquine Sulfate50$1,593
Mycophenolate Mofetil20$1,431
Metronidazole29$1,421
Ketoconazole95$1,402
Triamcinolone Acetonide122$1,381

Paid to pharmacies, not to this prescriber.

Other dermatology in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →